

EXUM

SCIENCE | SIMPLIFIED

THE WHY



MASSBOX



TYPICAL MASS SPECTROMETER

BUSINESS STATUS



TOOLS SOLD



Exum met their 2020 sales goal of selling 3 instruments (~\$1 million)

SPACE TO GROW



Present margins are 30-40% but a direct path exists to 62%

MARKET SIZE



Present market available in the domestic US is ~10,000 instruments per year

CUSTOMER FEEDBACK



Customer presentations end with statements like, "This is the instrument we have waited decades for"

DIFFICULT TO USE

TECHNICALLY INSUFFICIENT

EXPENSIVE

FRAGILE

LACKING A SINGLE INTERFACE

LEGACY
MASS SPEC

THE EXUM MASSBOX



EASY AS A SMARTPHONE

ANALYTICALLY SUPERIOR

AFFORDABLE

RUGGED


EXUM ECOSYSTEM (SaaS)

ENERGY SUCCESS

**ROCK, PIPES, BITS, FLANGES,
BATTERIES, SOLAR, ETC...**

Value Add

- Knowing what's in your material
- Knowing why it has failed
- Knowing how to make it better



**"Everyone in our group is raving
about the Massbox....it's hard to
concentrate on anything else..."**

Technical Director
O&G Service Co

THANK YOU

JEFF WILLIAMS, CEO AND CO-FOUNDER

JEFF@EXUMINSTRUMENTS.COM

813-480-0574

LOCATED IN DENVER, CO

WWW.EXUMINSTRUMENTS.COM

LINKEDIN

IF YOU ARE INTERESTED IN LEARNING
MORE ABOUT EXUM, PLEASE REACH OUT.

WE WILL BE CLOSING OUR A ROUND IN
Q2 2021.

CONFIDENTIAL DOCUMENT - THIS DOCUMENT HAS BEEN PROVIDED TO YOU WITH THE CONSENT OF EXUM INSTRUMENTS, INC. (THE "COMPANY") FOR INFORMATIONAL PURPOSES ONLY AND MAY NOT BE RELIED UPON BY YOU IN EVALUATING THE MERITS OF INVESTING IN ANY SECURITIES REFERRED TO HEREIN. THIS MATERIAL IS NOT INTENDED AS AN OFFER OR SOLICITATION WITH RESPECT TO THE PURCHASE OR SALE OF ANY FINANCIAL INSTRUMENT. ANY INVESTMENT DECISION WITH RESPECT TO SECURITIES OF THE COMPANY SHOULD BE MADE BY YOU BASED SOLELY UPON THE INFORMATION MADE AVAILABLE TO YOU IN THE CONTEXT OF YOUR INVESTIGATIONS OF AND DISCUSSIONS WITH THE COMPANY, IF AND WHEN YOU DETERMINE TO PROCEED WITH SUCH INVESTIGATIONS. IF A TRANSACTION INVOLVING THE EQUITY SECURITIES OF THE COMPANY SHOULD FOLLOW, ANY SUCH TRANSACTION WOULD NOT BE REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY OTHER JURISDICTION. THE COMPANY WOULD CONDUCT ANY SUCH TRANSACTION IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND OTHER APPLICABLE LAWS.

ANY PROJECTIONS OR OTHER FORWARD-LOOKING STATEMENTS INCLUDED IN THIS DOCUMENT ARE DEPENDENT UPON FUTURE EVENTS, SOME OF WHICH ARE NOT WITHIN THE CONTROL OF THE COMPANY, AND SHOULD NOT BE REGARDED AS A REPRESENTATION BY THE COMPANY THAT THE PROJECTED RESULTS WILL BE ACHIEVED. THESE STATEMENTS AND PROJECTIONS ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND UNDUE RELIANCE SHOULD NOT BE PLACED ON THEM. SUCH FORWARD-LOOKING STATEMENTS NECESSARILY INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES, WHICH MAY CAUSE ACTUAL PERFORMANCE AND FINANCIAL RESULTS IN FUTURE PERIODS TO DIFFER MATERIALLY FROM ANY PROJECTIONS OF FUTURE PERFORMANCE OR RESULT EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. ALTHOUGH FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESENTATION ARE BASED UPON WHAT MANAGEMENT OF THE COMPANY BELIEVES ARE REASONABLE ASSUMPTIONS, THERE CAN BE NO ASSURANCE THAT FORWARD-LOOKING STATEMENTS WILL PROVE TO BE ACCURATE, AS ACTUAL RESULTS AND FUTURE EVENTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN SUCH STATEMENTS.

THIS DOCUMENT IS STRICTLY CONFIDENTIAL AND MAY NOT BE REPRODUCED OR REDISTRIBUTED IN WHOLE OR IN PART NOR MAY THEIR CONTENTS BE DISCLOSED TO ANY OTHER PERSON.

THESE MATERIALS ARE SUBJECT TO CHANGE FROM TIME TO TIME WITHOUT NOTICE AND THE COMPANY IS NOT UNDER ANY OBLIGATION TO KEEP YOU ADVISED OF SUCH CHANGES. THE COMPANY DOES NOT MAKE ANY REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR COMPLETENESS OF THIS INFORMATION.

SCIENCE | SIMPLIFIED